Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need... Show more
APGE saw its Momentum Indicator move below the 0 level on March 28, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator turned negative. In of the 23 cases, the stock moved further down in the following days. The odds of a decline are at .
The 10-day RSI Indicator for APGE moved out of overbought territory on March 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 11 similar instances where the indicator moved out of overbought territory. In of the 11 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for APGE turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 13 similar instances when the indicator turned negative. In of the 13 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APGE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for APGE entered a downward trend on March 13, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
APGE moved above its 50-day moving average on April 02, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for APGE crossed bullishly above the 50-day moving average on March 19, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APGE advanced for three days, in of 107 cases, the price rose further within the following month. The odds of a continued upward trend are .
APGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.832) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.036).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. APGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor indicates that over the last year, APGE has been loosely correlated with SYRE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if APGE jumps, then SYRE could also see price increases.
Ticker / NAME | Correlation To APGE | 1D Price Change % | ||
---|---|---|---|---|
APGE | 100% | +6.23% | ||
SYRE - APGE | 47% Loosely correlated | +1.27% | ||
INZY - APGE | 46% Loosely correlated | +6.48% | ||
ELVN - APGE | 46% Loosely correlated | +5.19% | ||
ATXS - APGE | 45% Loosely correlated | +2.22% | ||
CRNX - APGE | 45% Loosely correlated | +2.51% | ||
More |